Ontology highlight
ABSTRACT:
SUBMITTER: Fox RJ
PROVIDER: S-EPMC6172944 | biostudies-literature | 2018 Aug
REPOSITORIES: biostudies-literature
Fox Robert J RJ Coffey Christopher S CS Conwit Robin R Cudkowicz Merit E ME Gleason Trevis T Goodman Andrew A Klawiter Eric C EC Matsuda Kazuko K McGovern Michelle M Naismith Robert T RT Ashokkumar Akshata A Barnes Janel J Ecklund Dixie D Klingner Elizabeth E Koepp Maxine M Long Jeffrey D JD Natarajan Sneha S Thornell Brenda B Yankey Jon J Bermel Robert A RA Debbins Josef P JP Huang Xuemei X Jagodnik Patricia P Lowe Mark J MJ Nakamura Kunio K Narayanan Sridar S Sakaie Ken E KE Thoomukuntla Bhaskar B Zhou Xiaopeng X Krieger Stephen S Alvarez Enrique E Apperson Michelle M Bashir Khurram K Cohen Bruce A BA Coyle Patricia K PK Delgado Silvia S Dewitt L Dana LD Flores Angela A Giesser Barbara S BS Goldman Myla D MD Jubelt Burk B Lava Neil N Lynch Sharon G SG Moses Harold H Ontaneda Daniel D Perumal Jai S JS Racke Michael M Repovic Pavle P Riley Claire S CS Severson Christopher C Shinnar Shlomo S Suski Valerie V Weinstock-Guttman Bianca B Yadav Vijayshree V Zabeti Aram A
The New England journal of medicine 20180801 9
<h4>Background</h4>There are limited treatments for progressive multiple sclerosis. Ibudilast inhibits several cyclic nucleotide phosphodiesterases, macrophage migration inhibitory factor, and toll-like receptor 4 and can cross the blood-brain barrier, with potential salutary effects in progressive multiple sclerosis.<h4>Methods</h4>We enrolled patients with primary or secondary progressive multiple sclerosis in a phase 2 randomized trial of oral ibudilast (≤100 mg daily) or placebo for 96 weeks ...[more]